title: Antiangiogenic treatment as a pre-operative management of alveolar soft-part sarcoma.
abstract: Alveolar soft-part sarcoma (ASPS) is a rare tumor. Cure is based solely on radical surgery. The general prognosis is poor. The tongue is an unusual site in adults, but not in children. Tumor removal can cause a severe impact on quality of life, even if reconstruction is possible. ASPS is a highly vascularized tumor and antiangiogenic therapy may have a role. We describe the use of the antiangiogenic combination bevacizumab and celecoxib in the preoperative management of a patient with an ASPS of the tongue.
authors: Department of Paediatric Oncology, Hospital Sant Joan de Déu, Barcelona, Spain.
authors: Nuria
authors: N
authors: Conde
authors: Ofelia
authors: O
authors: Cruz
authors: Asteria
authors: A
authors: Albert
authors: Jaume
authors: J
authors: Mora
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D000068579:Celecoxib; D002675:Child, Preschool; D005260:Female; D006801:Humans; D009389:Neovascularization, Pathologic / Q000175:diagnosis / Q000188:drug therapy*; D011720:Pyrazoles / Q000627:therapeutic use; D011788:Quality of Life; D018234:Sarcoma, Alveolar Soft Part / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery; D013449:Sulfonamides / Q000627:therapeutic use; D014062:Tongue Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D011720:Pyrazoles; D013449:Sulfonamides; D000068258:Bevacizumab; D000068579:Celecoxib